Q-omics provides the consensus-scored MMP24 profile across patient tissues and cancer cell-line models. MMP24 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MMP24 is differentially expressed in 15, with the highest sampling consensus in KIRP. Additionally, MMP24 RNA expression shows 19,856 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, KIRP, and ACC as cancer lineages where MMP24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MMP24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MMP24 survival associations across molecular data types. MMP24 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MMP24 RNA expression–survival associations across cancer types. High MMP24 expression shows unfavorable associations in BLCA and PCPG, but favorable associations in KIRC, LGG, HNSC and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MMP24 RNA expression.
This table summarizes MMP24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for MMP24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MMP24 shows lower tumor expression in LUSC, THCA and UCEC and higher tumor expression in KIRP, KIRC and LIHC. The KIRP box plot shows higher MMP24 RNA expression in tumor versus normal tissue (log2 FC = +1.175, t-test p < 0.001).
This table shows molecular features associated with MMP24 in patient tissues and cancer cell lines. In patient samples, MMP24 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MMP24 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
